Tracing immunity to human leishmaniasis

Future Microbiology

Volumn 4, Issue 2, 2009, Pages 241-254

  Nylén, Susanne ^a,b   Akuffo, Hannah ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

Antibody; Biomarker; Cytokine; Immune regulation; Leishmania; T cell

Indexed keywords

BACTERIUM ANTIBODY; BIOLOGICAL MARKER; CYTOKINE; INTERLEUKIN 10; LEISHMANIA VACCINE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; PROTOZOON ANTIBODY;

CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESEARCH; DRUG SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNITY; IMMUNOREGULATION; INFECTION SENSITIVITY; LEISHMANIA; LEISHMANIASIS; LEISHMANIN SKIN TEST; MACROPHAGE ACTIVATION; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; PROTECTION; REVIEW; VISCERAL LEISHMANIASIS; ANIMAL; BLOOD; IMMUNOLOGY; SECRETION;

ANIMALS; ANTIBODIES, PROTOZOAN; CYTOKINES; HUMANS; LEISHMANIA; LEISHMANIASIS;

EID: 63849274016     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460913.4.2.241     Document Type: Review

References (114)

1. Tuon FF, Gomes-Silva A, Da-Cruz AM, Duarte MI, Neto VA, Amato VS: Local immunological factors associated with recurrence of mucosal leishmaniasis. Clin. Immunol. 128(3), 442-446 (2008).
2. Peters NC, Egen JG, Secundino N et al.: In vivo imaging reveals an essential role for neutrophils in leishmaniasis transmitted by sand flies. Science 321 (5891), 970-974 (2008).
3. Ng LG, Hsu A, Mandell MA et al.: Migratory dermal dendritic cells act as rapid sensors of protozoan parasites. PLoS Pathog. 4 (11), e1000222 (2008).
4. Laskay T, RollinghoffM, Solbach W: Natural killer cells participate in the early defense against Leishmania major infection in mice. Eur. J. Immunol. 23(9), 2237-2241 (1993).
5. Nylen S, Maasho K, Soderstrom K, Ilg T, Akuffo H: Live Leishmanialaromastigotes can directly activate primary human natural killer cells to produce interferon-7. Clin. Exp. Immunol. 131(3), 457-467 (2003).
6. Maasho K, Satti I, Nylen S, Guzman G, Koning F, Akuffo H: A Leishmania homologue of receptors for activated C-kinase (LACK) induces both interferon-7 and interleukin-10 in natural killer cells of healthy blood donors. J. Infect. Dis. 182(2), 570-578 (2ooo).
7. Lieke T, Nylen S, Eidsmo L et al.: Leishmania surface protein gp63 binds directly to human natural killer cells and inhibits proliferation. Clin. Exp. Immunol. 153 (2), 221-230 (2008).
8. Pahwa R, Gupta SK, Singh T, Nigam S: Acute fulminant visceral leishmaniasis in children - a report of two cases. Indian J. Pathol. Microbiol. 47(3), 428-430 (2004).
9. McFarlane E, Perez C, Charmoy M et al.: Neutrophils contribute to development of a protective immune response during onset of infection with Leishmania donovani. Infect. Immun. 76(2), 532-541 (2008).
10. Lodge R, Descoteaux A: Modulation of phagolysosome biogenesis by the lipophosphoglycan of Leishmania. Clin. Immunol. 114(3), 256-265 (2005).
11. Desjardins M, Descoteaux A: Survival strategies of Leishmania donovani in mammalian host macrophages. Res. Immunol. 149(7-8), 689-692 (1998).
12. McConville MJ, Turco SJ, Ferguson MA, Sacks DL: Developmental modification of lipophosphoglycan during the differentiation of Leishmania major promastigotes to an infectious stage. EMBO J. 11(10), 3593-3600 (1992).
13. Wurco SJ, Sacks DL: Expression of a stage-specific lipophosphoglycan in Leishmania major amastigotes. Mol. Biochem. Parasitol. 45(1), 91-99 (1991).
14. Gueirard P, Laplante A, Rondeau C, Milon G, Desjardins M: Trafficking of Leishmania donovani promastigotes in non-lytic compartments in neutrophils enables the subsequent transfer of parasites to macrophages. Cell Microbiol. 10 (1), 100-111 (2008).
15. Lodge R, Diallo TO, Descoteaux A: Leishmania donovani lipophosphoglycan blocks NADPH oxidase assembly at the phagosome membrane. Cell Microbiol. 8(12), 1922-1931 (2006).
16. Tejle K, Lindroth M, Magnusson KE, Rasmusson B: Wild-type Leishmania donovani promastigotes block maturation, increase integrin expression and inhibit detachment of human monocyte-derived dendritic cells: the influence of phosphoglycans. FEMS Microbiol. Lett. 279(1), 92-102 (2008).
17. Sacks DL, Perkins PV: Identification of an infective stage of Leishmania promastigotes. Science 223 (4643), 1417-1419 (1984).
18. Antoine JC, Lang T, Prina E, Courret N, Hellio R: H-2M molecules, like MHC class II molecules, are targeted to parasitophorous vacuoles of Leishmania-infected macrophages and internalized by amastigotes of L. amazonensis and L. mexicana. J. Cell Sci. 112(Pt 15), 2559-2570 (1999).
19. Belkaid Y, Butcher B, Sacks DL: Analysis of cytokine production by inflammatory mouse macrophages at the single-cell level: selective impairment of IL-12 induction in Leishmania-infected cells. Eur. J. Immunol. 28 (4), 1389-1400 (1998).
20. Jayakumar A, Widenmaier R, Ma X, McDowell MA: Transcriptional inhibition of interleukin-12 promoter activity in Leishmania spp.-infected macrophages. J. Parasitol. 94(1), 84-93 (2008).
21. Soong L: Modulation of dendritic cell function by Leishmania parasites. J. Immunol. 180(7), 4355-4360 (2008).
22. Xin L, Li K, Soong L: Down regulation of dendritic cell signaling pathways by Leishmania amazonensis amastigotes. Mol. Immunol. 45(12), 3371-3382 (2008).
23. De Souza Leao S, Lang T, Prina E, Hellio R, Antoine JC: Intracellular Leishmania amazonensis amastigotes internalize and degrade MHC class II molecules of their host cdls. J. Cell Sci. 108(Pt 10), 3219-3231 (1995).
24. Osorio y Fortéa J, Prina E, de La Llave E, Lecoeur H, Lang T, Milon G: Unveiling pathways used by Leishmania amazonensis amastigotes to subvert macrophage function. Immunol. Rev. 219, 66-74 (2007).
25. Nylen S, Sacks D: Interleukin-10 and the pathogenesis of human visceral leishmaniasis. Trends Immunol. 28(9), 378-384 (2007).
26. Sacks D, Noben-Trauth N: The immunology of susceptibility and resistance to Leishmania major in mice. Nat. Rev. Immunol. 2(11), 845-858 (2002).
27. Karp CL, el-Safi SH, Wynn TA et al.: In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-γ. J. Clin. Invest. 91(4), 1644-1648 (1993).
28. Kenney RT, Sacks DL, Gam AA, Murray HW, Sundar S: Splenic cytokine responses in Indian kala-azar before and after treatment. J. Infect. Dis. 177(3), 815-818 (1998).
29. Park AY, Hondowicz BD, Scott P: IL-12 is required to maintain a Thl response during Leishmania major infection. J. Immunol. 165 (2), 896-902 (2000).
30. Kima PE: The amastigote forms of Leishmania are experts at exploiting host cell processes to establish infection and persist. Int. J. Parasitol. 37(10), 1087-1096 (2007).
31. von Stebut E, Belkaid Y, Jakob T, Sacks DL, Udey MC: Uptake of Leishmania major amastigotes results in activation and interleukin 12 release from murine skin-derived dendritic cells: implications for the initiation of anti-Leishmania immunity. J. Exp. Med. 188(8), 1547-1552 (1998).
32. McDowell MA, Marovich M, Lira R, Braun M, Sacks D: Leishmania priming of human dendritic cells for CD40 ligand-induced interleukin-12p70 secretion is strain and species dependent. Infect. Immun. 70 (8), 3994-4001 (2002).
33. Prina E, Abdi SZ, Lebastard M, Perret E, Winter N, Antoine JC: Dendritic cells as host cells for the promastigote and amastigote stages of Leishmania amazonensis: the role of opsonins in parasite uptake and dendritic cell maturation. J. Cell Sci. 117(Pt 2), 315-325 (2004).
34. Favali C, Tavares N, Clarencio J, Barral A, Barral-Netto M, Brodskyn C: Leishmania amazonensis infection impairs differentiation and function of human dendritic cells. J. Leukoc. Biol. 82(6), 1401-1406 (2007).
35. Donovan MJ, Jayakumar A, McDowell MA: Inhibition of groups 1 and 2 CD1 molecules on human dendritic cells by Leishmania species. Parasite Immunol. 29(10), 515-524 (2007).
36. Amprey JL, Spath GF, Porcelli SA: Inhibition of CD1 expression in human dendritic cells during intracellular infection with Leishmania donovani. Infect. Immun. 72(1), 589-592 (2004).
37. Xavier MB, Silveira FT, Demachki S, Ferreira MM, do Nascimento JL: American tegumentary leishmaniasis: a quantitative analysis of Langerhans cells presents important differences between L. amazonensis and Viannia subgenus. Acta Trop. 95 (1), 67-73 (2005).
38. Silveira FT, Lainson R, Gomes CM, Laurenti MD, Corbett CE: Reviewing the role of the dendritic Langerhans cells in the immunopathogenesis of American cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 102(11), 1075-1080 (2008).
39. Meymandi S, Dabiri S, Dabiri D, Crawford RI, Kharazmi A: A quantitative study of epidermal Langerhans cells in cutaneous leishmaniasis caused by Leishmania tropica. Int. J. Dermatol. 43(11), 819-823 (2004).
40. + splenic dendritic cell functions in murine visceral leishmaniasis: correlation with parasite replication in the spleen. Immunology 99(2), 305-313 (2000).
41. Smelt SC, Engwerda CR, McCrossen M, Kaye PM: Destruction of follicular dendritic cells during chronic visceral leishmaniasis. J. Immunol. 158(8), 3813-3821 (1997).
42. Svensson M, Maroof A, Ato M, Kaye PM: Stromal cells direct local differentiation of regulatory dendritic cells. Immunity 21 (6), 805-816 (2004).
43. + T cells from healthy donors and patients with kala-azar. J. Infect. Dis. 194(3), 294-301 (2006).
44. + regulatory T cells control Leishmania major persistence and immunity. Nature 420 (6915), 502-507 (2002).
45. Zaph C, Uzonna J, Beverley SM, Scott P: Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites. Nat. Med. 10(10), 1104-1110 (2004).
46. Modabber F: Vaccines against leishmaniasis. Ann. Trop. Med. Parasitol. 89(Suppl. 1), 83-88 (1995).
47. Noazin S, Modabber F, Khamesipour A et al.: First generation leishmaniasis vaccines: a review of field efficacy trials. Vaccine 26(52), 6759-6767 (2008).
48. Reed SG: Diagnosis of leishmaniasis. Clin. Dermatol. 14(5), 471-478 (1996).
49. Bern C, Amann J, Haque R et al.: Loss of leishmanin skin test antigen sensitivity and potency in a longitudinal study of visceral leishmaniasis in Bangladesh. Am. J. Trop. Med. Hyg. 75 (4), 744-748 (2006).
50. Nylen S, Khamesipour A, Mohammadi A et al.: Surrogate markers of immunity to Leishmania major in leishmanin skin test negative individuals from an endemic area re-visited. Vaccine 24(47-48), 6944-6954 (2006).
51. Khamesipour A, Dowlati Y, Asilian A et al.: Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine 23 (28), 3642-3648 (2005).
52. Zwingenberger K, Harms G, Pedrosa C, Omena S, Sandkamp B, Neifer S: Determinants of the immune response in visceral leishmaniasis: evidence for predominance of endogenous interleukin 4 over interferon-γ production. Clin. Immunol. Immunopathol. 57(2), 242-249 (1990).
53. + T-cell response to Leishmania parasites. APMIS 102(2), 81-88 (1994).
54. Da-Cruz AM, Bittar R, Mattos M et al.: T-cell-mediated immune responses in patients with cutaneous or mucosal leishmaniasis: long-term evaluation after therapy. Clin. Diagn. Lab. Immunol. 9(2), 251-256 (2002).
55. Pirmez C, Yamamura M, Uyemura K, Paes-Oliveira M, Conceicao-Silva F, Modlin RL: Cytokine patterns in the pathogenesis of human leishmaniasis. J. Clin. Invest. 91(4), 1390-1395 (1993).
56. Kemp M, Kurtzhals JA, Kharazmi A, Theander TG: Interferon-γ and interleukin-4 in human Leishmania donovani infections. Immunol. Cell Biol. 71(Pt 6), 583-587 (1993).
57. + (Foxp3) regulatory T cells in human visceral leishmaniasis. J. Exp. Med. 204(4), 805-817 (2007).
58. Anderson CF, Mendez S, Sacks DL: Nonhealing infection despite Thl polarization produced by a strain of Leishmania major in C57BL/6 mice. J. Immunol. 174(5), 2934-2941 (2005).
59. Ji J, Sun J, Qi H, Soong L: Analysis of T helper cell responses during infection with Leishmania amazonensis. Am. J. Trop. Med. Hyg. 66(4), 338-345 (2002).
60. Ghalib HW, Piuvezam MR, Skeiky YA et al.: Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J. Clin. Invest. 92(1), 324-329 (1993).
61. +CD25-Foxp3-Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis. J. Exp. Med. 204(2), 285-297 (2007).
62. Murphy ML, Wille U, Villegas EN, Hunter CA, Farrell Jp: IL-10 mediates susceptibility to Leishmania donovani infection. Eur. J. Immunol. 31(10), 2848-2856 (2001).
63. Akuffo H, Maasho K, Blostedt M, Hojeberg B, Britton S, Bakhiet M: Leishmania aethiopica derived from diffuse leishmaniasis patients preferentially induce mRNA for interleukin-10 while those from localized leishmaniasis patients induce interferon-γ. J. Infect. Dis. 175(3), 737-741 (1997).
64. Saha S, Mondal S, Ravindran R et al.: IL-10- and TGF-β-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India. J. Immunol. 179(8), 5592-5603 (2007).
65. Salhi A, Rodrigues V Jr, Santoro F et al.: Immunological and genetic evidence for a crucial role of IL-10 in cutaneous lesions in humans infected with Leishmania braziliensis. J. Immunol. 180(9), 6139-6148 (2008).
66. Barral A, Teixeira M, Reis P et al.: Transforming growth factor-β in human cutaneous leishmaniasis. Am. J. Pathol. 147(4), 947-954 (1995).
67. Barral-Netto M, Barral A, Brownell CE et al.: Transforming growth factor-β in leishmanial infection: a parasite escape mechanism. Science 257(5069), 545-548 (1992).
68. Favali C, Costa D, Afonso L et al.: Role of costimulatory molecules in immune response of patients with cutaneous leishmaniasis. Microbes Infect. 7(1), 86-92 (2005).
69. Anderson CF, Lira R, Kamhawi S, Belkaid Y, Wynn TA, Sacks D: IL-10 and TGF-β control the establishment of persistent and transmissible infections produced by Leishmania tropica in C57BL/6 mice. J. Immunol. 180(6), 4090-4097 (2008).
70. Cenini P, Berhe N, Hailu A, McGinnes K, Frommel D: Mononuclear cell subpopulations and cytokine levels in human visceral leishmaniasis before and after chemotherapy. J. Infect. Dis. 168 (4), 986-993 (1993).
71. Kurkjian KM, Mahmutovic AJ, Kellar KL, Haque R, Bern C, Secor WE: Multiplex analysis of circulating cytokines in the sera of patients with different clinical forms of visceral leishmaniasis. Cytometry A 69(5), 353-358 (2006).
72. + monocytes are hallmarks of active human visceral leishmaniasis due to Leishmania chagasi infection. Clin. Exp. Immunol. 146(1), 124-132 (2006).
73. van der Poll T, Zijlstra EE, Mevissen M: Interleukin 6 during active visceral leishmaniasis and after treatment. Clin. Immunol. Immunopathol. 77(1), 111-114 (1995).
74. Gasim S, Elhassan AM, Kharazmi A, Khalil EA, Ismail A, Theander TG: The development of post-kala-azar dermal leishmaniasis (PKDL) is associated with acquisition of Leishmania reactivity by peripheral blood mononuclear cells (PBMC). Clin. Exp. Immunol. 119(3), 523-529 (2000).
75. Gasim S, Elhassan AM, Khalil EA et al.: High levels of plasma IL-10 and expression of IL-10 by keratinocytes during visceral leishmaniasis predict subsequent development of post-kala-azar dermal leishmaniasis. Clin. Exp. Immunol. 111 (1), 64-69 (1998).
76. Castes M, Wrujillo D, Rojas ME et al.: Serum levels of tumor necrosis factor in patients with American cutaneous leishmaniasis. Biol. Res. 26(1-2), 233-238 (1993).
77. Da-Cruz AM, de Oliveira ME de Luca PM, Mendonca SC, Coutinho SG: Tumor necrosis factor-α in human American tegumentary leishmaniasis. Mere. Inst. Oswaldo Cruz 91(2), 225-229 (1996).
78. Bagalas V, Kioumis I, Argyropoulou P, Patakas D: Visceral leishmaniasis infection in a patient with rheumatoid arthritis treated with etanercept. Clin. Rheumatol. 26(8), 1344-1345 (2007).
79. Muniz-Junqueira MI, de Paula-Coelho VN: Meglumine antimonate directly increases phagocytosis, superoxide anion and TNF-α production, but only via TNF-α it indirectly increases nitric oxide production by phagocytes of healthy individuals, in vitro. Int. Immunopharmacol. 8(12), 1633-1638 (2008).
80. Stanley AC, Engwerda CR: Balancing immunity and pathology in visceral leishmaniasis. Immunol. Cell Biol. 85 (2), 138-147 (2007).
81. Gaze ST, Dutra WO, Lessa M et al.: Mucosal leishmaniasis patients display an activated inflammatory T-cell phenotype associated with a nonbalanced monocyte population. Scand. J. Immunol. 63 (1), 70-78 (2006).
82. Ribeiro-de-Jesus A, Almeida RP, Lessa H, Bacellar O, Carvalho EM: Cytokine profile and pathology in human leishmaniasis. Braz. J. Med. Biol. Res. 31(1), 143-148 (1998).
83. Antonelli LR, Dutra WO, Almeida RP, Bacellar O, Carvalho EM, Gollob KJ: Activated inflammatory T cells correlate with lesion size in human cutaneous leishmaniasis. Immunol. Lett. 101 (2), 226-230 (2005).
84. Melby PC, Andrade-Narvaez F, Darnell BJ, Valencia-Pacheco G: In situ expression of interleukin-10 and interleukin-12 in active human cutaneous leishmaniasis. FEMS Immunol. Med. Microbiol. 15 (2-3), 101-107 (1996).
85. Ganguly S, Das NK, Panja M et al.: Increased levels of interleukin-10 and IgG3 are hallmarks of Indian post-kala-azar dermal leishmaniasis. J. Infect. Dis. 197(12), 1762-1771 (2008).
86. Louzir H, Melby PC, Ben Salah A et al.: Immunologic determinants of disease evolution in localized cutaneous leishmaniasis due to Leishmania major. J. Infect. Dis. 177(6), 1687-1695 (1998).
87. Ritter U, Korner H: Divergent expression of inflammatory dermal chemokines in cutaneous leishmaniasis. Parasite Immunol. 24(6), 295-301 (2002).
88. Akuffo HO, Fehniger TE, Britton S: Differential recognition of Leishmania aethiopica antigens by lymphocytes from patients with local and diffuse cutaneous leishmaniasis. Evidence for antigen-induced immune suppression. J. Immunol. 141(7), 2461-2466 (1988).
89. Schonian G, Akuffo H, Lewin S et al.: Genetic variability within the species Leishmania aethiopica does not correlate with clinical variations of cutaneous leishmaniasis. Mol. Biochem. Parasitol. 106(2), 239-248 (2000).
90. Kane MM, Mosser DM: The role of IL-10 in promoting disease progression in leishmaniasis. J. Immunol. 166(2), 1141-1147 (2001).
91. Buxbaum LU: A detrimental role for IgG and FchγR in Leishmania mexicana infection. Immunol. Res. 42(1-3), 197-209 (2008).
92. Buxbaum LU, Scott P: Interleukin 10- and Fcγ receptor-deficient mice resolve Leishmania mexicana lesions. Infect. Immun. 73 (4), 2101-2108 (2005).
93. Anam K, Afrin F, Banerjee D et al.: Immunoglobulin subclass distribution and diagnostic value of Leishmania donovani antigen-specific immunoglobulin G3 in Indian kala-azar patients. Clin. Diagn. Lab. Immunol. 6(2), 231-235 (1999).
94. Anam K, Afrin F, Banerjee D et al.: Differential decline in Leishmania membrane antigen-specific immunoglobulin G (IgG), IgM, IgE, and IgG subclass antibodies in Indian kala-azar patients after chemotherapy. Infect. Immun. 67(12), 6663-6669 (1999).
95. Elassad AM, Younis SA, Siddig M, Grayson J, Petersen E, Ghalib HW: The significance of blood levels of IgM, IgA, IgG and IgG subclasses in Sudanese visceral leishmaniasis patients. Clin. Exp. Immunol. 95 (2), 294-299 (1994).
96. Cillari E, Vitale G, Arcoleo F et al.: In vivo and in vitro cytokine profiles and mononuclear cell subsets in Sicilian patients with active visceral leishmaniasis. Cytokine 7(7), 740-745 (1995).
97. Eidsmo L, Wolday D, Berhe N et al.: Alteration of Fas and Fas ligand expression during human visceral leishmaniasis. Clin. Exp. Immunol. 130(2), 307-313 (2002).
98. + lymphocyte subset and monocyte apoptosis in patients with acute visceral leishmaniasis. Immunology 113 (2), 260-268 (2004).
99. Eidsmo L, Fluur C, Rethi B et al.: FasL and TRAIL induce epidermal apoptosis and skin ulceration upon exposure to Leishmania major. Am. J. Pathol. 170(1), 227-239 (2007).
100. Eidsmo L, Nylen S, Khamesipour A, Hedblad MA, Chiodi F, Akuffo H: The contribution of the Fas/FasL apoptotic pathway in ulcer formation during Leishmania major-induced cutaneous leishmaniasis. Am. J. Pathol. 166(4), 1099-1108 (2005).
101. Rohtagi A, Agarwal SK, Bose M, Chattopadhya D, Saha K: Blood, bone marrow and splenic lymphocyte subset profiles in Indian visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 90 (4), 431-434 (1996).
102. Barral-Netto M, Barral A, Brodskyn C, Carvalho EM, Reed SG. Cytotoxicity in human mucosal and cutaneous leishmaniasis. Parasite Immunol. 17(1), 21-28 (1995).
103. Brodskyn CI, Barral A, Boaventura V, Carvalho E, Barral-Netto M: Parasite-driven in vitro human lymphocyte cytotoxicity against autologous infected macrophages from mucosal leishmaniasis. J. Immunol. 159(9), 4467-4473 (1997).
104. Veress B, Omer A, Satir AA, El Hassan AM: Morphology of the spleen and lymph nodes in fatal visceral leishmaniasis. Immunology 33(5), 607-610 (1977).
105. Maasho K, Sanchez F, Schurr E, Hailu A, Akuffo H: Indications of the protective role of natural killer cells in human cutaneous leishmaniasis in an area of endemicity. Infect Immun. 66(6), 2698-2704 (1998).
106. + T cells without affecting cellular immune responses. Microbiol. Immunol. 51(10), 1003-1011 (2007).
107. Wolday D, Berhe N, Britton S, Akuffo H: HIV-1 alters T helper cytokines, interleukin-12 and interleukin-18 responses to the protozoan parasite Leishmania donovani. AIDS 14(8), 921-929 (2000).
108. Berhe N, Wolday D, Hailu A et al.: HIV viral load and response to antileishmanial chemotherapy in co-infected patients. AIDS 13(14), 1921-1925 (1999).
109. + T-cell activation-induced human immunodeficiency virus replication. Infect. Immun. 67(10), 5258-5264 (1999).
110. Wolday D, Berhe N, Akuffo H, Britton S: Leishmania-HIV interaction: immunopathogenic mechanisms. Parasitol. Today 15(5), 182-187 (1999).
111. Trudel N, Garg R, Messier N, Sundar S, Ouellette M, Tremblay MJ: Intracellular survival of Leishmania species that cause visceral leishmaniasis is significantly reduced by HIV-1 protease inhibitors. J. Infect. Dis. 198(9), 1292-1299 (2008).
112. Garcia-Garcia JA, Martin-Sanchez J, Gallego M et al.: Use of noninvasive markers to detect Leishmania infection in asymptomatic human immunodeficiency virus-infected patients. J. Clin. Microbiol. 44(12), 4455-4458 (2006).
113. Martin-Sanchez J, Pineda JA, Morillas-Marquez F, Garcia-Garcia JA, Acedo C, Macias J: Detection of Leishmania infantum kinetoplast DNA in peripheral blood from asymptomatic individuals at risk for parenterally transmitted infections: relationship between polymerase chain reaction results and other Leishmania infection markers. Am. J. Trop. Med. Hyg. 70(5), 545-548 (2004).
114. Sundar S, Rai M: Laboratory diagnosis of visceral leishmaniasis. Clin. Diagn. Lab. Immunol. 9(5), 951-958 (2002).